Sortino, Rosalba, Gonzalez-Diez, Aleix, Milla-Navarro, Santiago, Martinez-Tambella, Joaquin, Paleo-Garcia, Victor, Calatayud, Eric, de Saralegui, Paula, Opar, Ekin, Claparols, Alvar, Quintanilla, Josecarlo A, Martinez-Soler, Xavier, Riefolo, Fabio, Matera, Carlo, Hernando, Jordi, Gomila, Alexandre M J, Perez-Batlle, Gerard, Pereira, Carles, Camarero, Nuria, Serra, Carme, Gomez-Santacana, Xavier, Llebaria, Amadeu, Rovira, Xavier, de la Villa, Pedro, Gorostiza, Pau, (2026). Restoration of SaccadicEye Movements and VisuallyGuided Behavior in Ambient White Light with Photoswitchable SmallMoleculesJOURNAL OF THE AMERICAN CHEMICAL SOCIETY 148, 31701-31715
Blinding diseases due to the degeneration of photoreceptors (PhRs), such as geographic atrophy (GA) secondary to dry age-related macular degeneration and retinitis pigmentosa (RP), leave the rest of the retinal circuitry largely intact, albeit unable to respond to light. Gene therapy has been able to revert PhR degeneration, but it can be applied only to a rare mutation affecting a small subset of RP patients. Alternatively, implanted electronic retinal prostheses aim at a larger population by electrically stimulating surviving neurons. However, the treatment is invasive and costly and provides limited resolution. Photopharmacology can develop photoswitchable small molecules to restore vision impairment by conferring light sensitivity to ion channels that are widely expressed in the remaining inner retinal neurons, and a first-in-human clinical trial is ongoing. Here, we have developed novel photoswitchable small-molecule ligands of metabotropic glutamate 6 (mGlu6) receptors, which are located exclusively at the dendrites of ON bipolar cells (postsynaptic to PhRs) and can leverage a privileged position to mimic physiological signals in the remnant retinal circuit. These photoswitchable ligands (prosthe6) thus act as "molecular prostheses" that can restore the light input to the retina via upstream-targeted control of the circuit after PhR degeneration. Prosthe6 compounds are allosteric, drug-like, water-soluble, and display outstanding in vitro properties including full efficacy, nanomolar potency, fast deactivation in ambient white light, and fast reactivation in the dark. In vivo experiments show that they readily recover the saccadic eye movements of blinded zebrafish larvae and restore the innate light-avoidance behavior in the mouse models of blindness (GA and RP). These effects are mediated by mGlu6 receptors in vivo. In addition, at least two compounds (prosthe6-12 and -15) can restore sight by topical administration and display promising safety properties to become potential drug candidates for sight restoration in patients with degenerative blinding diseases.
Camarero, N., Trapero, A., Pérez-Jiménez, A., Macia, E., Gomila-Juaneda, A., Martín-Quirós, A., Nevola, L., Llobet, A., Llebaria, A., Hernando, J., Giralt, E., Gorostiza, P., (2020). Photoswitchable dynasore analogs to control endocytosis with lightChemical Science 11, (33), 8981-8988
The spatiotemporal control of cellular dynamic processes has great fundamental interest but lacks versatile molecular tools. Dynamin is a key protein in endocytosis and an appealing target to manipulate cell trafficking using patterns of light. We have developed the first photoswitchable small-molecule inhibitors of endocytosis (dynazos), by a stepwise design of the photochromic and pharmacological properties of dynasore, a dynamin inhibitor. We have characterized their photochromism with UV-visible and transient absorption spectroscopy and their biological activity using fluorescence microscopies and flow cytometry. Dynazos are water-soluble, cell permeable, and photostable, and enable fast, single-wavelength photoswitchable inhibition of clathrin-mediated endocytosis at micromolar concentration.
Matera, C., Gomila, A. M. J., Camarero, N., Libergoli, M., Soler, C., Gorostiza, P., (2019). Photochromic antifolate for light-activated chemotherapyProceedings of SPIE 17th International Photodynamic Association World Congress , SPIE (Cambridge, USA) 11070, 110709H
Although cytotoxic chemotherapy is one of the primary pharmacological treatments for chronic hyperproliferative diseases such as cancer and psoriasis, its efficacy and tolerability are in many cases dramatically limited by off-target toxicity. A promising approach to improve these therapies is to activate the drugs exclusively at their desired place of action. In fact, in those diseases that would benefit from a highly localized treatment, a precise spatiotemporal control over the activity of a chemotherapeutic agent would allow reducing the concentration of active compound outside the targeted region, improving the tolerability of the treatment. Light is a powerful tool in this respect: it offers unparalleled opportunities as a non-invasive regulatory signal for pharmacological applications because it can be delivered with high precision regarding space, time, intensity and wavelength. Photopharmacology represents a new and emerging approach in this regard since the energy of light is used to change the structure of the drug and hence to switch its pharmacological activity on and off on demand. We describe here phototrexate, the first light-regulated inhibitor of the human DHFR. Enzyme and cell viability assays demonstrated that phototrexate behaves as a potent antifolate in its cis configuration, obtained under UVA illumination, and that it is nearly inactive in its dark-relaxed trans form. Experiments in zebrafish confirmed that phototrexate can disrupt folate metabolism in a light-dependent fashion also in vivo. Overall, phototrexate represents a potential candidate towards the development of an innovative photoactivated antifolate chemotherapy.
Ruiz, Marta P., Aragones, Albert C., Camarero, Nuria, Vilhena, J. G., Ortega, Maria, Zotti, Linda Angela, Perez, Ruben, Cuevas, Juan Carlos, Gorostiza, Pau, Díez-Pérez, Ismael, (2017). Bioengineering a single-protein junctionJournal of the American Chemical Society 139, (43), 15337–15346
Bioelectronics moves toward designing nanoscale electronic platforms that allow in vivo determinations. Such devices require interfacing complex biomolecular moieties as the sensing units to an electronic platform for signal transduction. Inevitably, a systematic design goes through a bottom-up understanding of the structurally related electrical signatures of the biomolecular circuit, which will ultimately lead us to tailor its electrical properties. Toward this aim, we show here the first example of bioengineered charge transport in a single-protein electrical contact. The results reveal that a single point-site mutation at the docking hydrophobic patch of a Cu-azurin causes minor structural distortion of the protein blue Cu site and a dramatic change in the charge transport regime of the single-protein contact, which goes from the classical Cu-mediated two-step transport in this system to a direct coherent tunneling. Our extensive spectroscopic studies and molecular-dynamics simulations show that the proteins’ folding structures are preserved in the single-protein junction. The DFT-computed frontier orbital of the relevant protein segments suggests that the Cu center participation in each protein variant accounts for the different observed charge transport behavior. This work is a direct evidence of charge transport control in a protein backbone through external mutagenesis and a unique nanoscale platform to study structurally related biological electron transfer.
Izquierdo-Serra, M., Bautista-Barrufet, A., Trapero, A., Garrido-Charles, A., Diaz-Tahoces, A., Camarero, N., Pittolo, S., Valbuena, S., Perez-Jimenez, A., Gay, M., Garcia-Moll, A., Rodriguez-Escrich, C., Lerma, J., De La Villa, P., Fernandez, E., Pericas, M. A., Llebaria, A., Gorostiza, P., (2016). Optical control of endogenous receptors and cellular excitability using targeted covalent photoswitchesNature Communications 7, 12221
Light-regulated drugs allow remotely photoswitching biological activity and enable plausible therapies based on small molecules. However, only freely diffusible photochromic ligands have been shown to work directly in endogenous receptors and methods for covalent attachment depend on genetic manipulation. Here we introduce a chemical strategy to covalently conjugate and photoswitch the activity of endogenous proteins and demonstrate its application to the kainate receptor channel GluK1. The approach is based on photoswitchable ligands containing a short-lived, highly reactive anchoring group that is targeted at the protein of interest by ligand affinity. These targeted covalent photoswitches (TCPs) constitute a new class of light-regulated drugs and act as prosthetic molecules that photocontrol the activity of GluK1-expressing neurons, and restore photoresponses in degenerated retina. The modularity of TCPs enables the application to different ligands and opens the way to new therapeutic opportunities.
Control of membrane traffic: Photoswitchable inhibitors of protein-protein interactions were applied to photoregulate clathrin-mediated endocytosis (CME) in living cells. Traffic light (TL) peptides acting as "stop" and "go" signals for membrane traffic can be used to dissect the role of CME in receptor internalization and in cell growth, division, and differentiation.
Cookies are important to you: they influence your browsing experience, help us protect your privacy, and allow us to process the requests you make through the website. We use our own and third-party cookies to analyze our services and show you advertising related to your preferences, based on a profile created from your browsing habits. You can “Accept” or “Reject” non-essential cookies, as well as configure your preferences by clicking “Configure Cookies.” For more information, please consult our Cookie Policy.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.